| Bioactivity | SHEN26 (ATY014) is a potent and orally active RdRp inhibitor, with an IC50 for SARS-CoV-2 is 1.36 μM. SHEN26 is a 5’-cyclohexanecarboxylate derivative of GS-441524 (HY-103586). SHEN26 inhibits viral nucleic acid synthesis to achieve antiviral effects. SHEN26 can be used for coronavirus disease 2019 (COVID-19) treatment.[1][2]. | ||||||||||||
| Invitro | SHEN26 (ATY014) 对 beta 和 delta 变体的 IC50 分别为 1.12 μM 和0.35 μM[1]。 0 --> SHEN26 相关抗体: | ||||||||||||
| Name | SHEN26 | ||||||||||||
| CAS | 2691076-98-7 | ||||||||||||
| Formula | C19H23N5O5 | ||||||||||||
| Molar Mass | 401.42 | ||||||||||||
| Appearance | 固体 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Chen Q, et al. Optimized Kilogram-Scale Synthesis and Impurity Identification of SHEN26 (ATV014) for Treating COVID-19. Organic Process Research & Development. 2023 Nov 20. [2]. Ji X, et al. Research and development of Chinese anti-COVID-19 drugs. Acta Pharm Sin B. 2022 Dec;12(12):4271-4286. |